New Players in MS
October 30, 2010
The copyright for all illustrations and pictures has been heeded by all authors to the best of their knowledge. If you feel your copyright has been infringed in any way or if you have any questions, do contact us by clicking on this link, please.
|Congress:||The 4th World Congress on Controversies in Neurology (CONy)|
Dimethyl fumarate (BG 00012), licensed for the treatment of psoriasis, has been shown to provide positive effects in MS patients. The exact mechanism of action of BG00012 is unknown. Nonclinical studies have demonstrated that fumaric acid esters may modulate the immune system through enhancement of the Nrf2 signaling pathway. This leads to inhibition of expression of pro-inflammatory mediators such as Il-1ß, IL-6, TNF-?, and potentially provide cytoprotection effect. In vitro studies have shown that dimetyl fumarate can induce also the expression of anti-inflammatory cytokines such as IL- 4, IL-5 or IL-10. Cell and tissue protection is connected with induction of detoxifying and antioxidant enzymes. In Phase II study 257 patients with relapsing remitting multiple sclerosis, aged 18-55 years, were randomized to receive BG00012 120 mg once daily (n=64), 120 mg three times daily (n=64), 240 mg three times daily (n=64) or placebo(n=65) for 24 weeks.
|Category:||Neurology; Multiple Sclerosis; treatment;|